The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27
Open accessAbstract
Purpose: The limited information on predictors of locoregional recurrence (LRR) after neoadjuvant chemotherapy (NC) has resulted in controversy about the optimal use of adjuvant radiotherapy and the timing of sentinel lymph node biopsy. Patients and Methods: We examined patterns and predictors of LRR as first event in combined analysis of two National Surgical Adjuvant Breast and Bowel Project (NSABP) neoadjuvant trials. NC was either doxorubicin/cyclophosphamide (AC) alone or AC followed by neoadjuvant/adjuvant docetaxel. Lumpectomy patients received breast radiotherapy alone; mastectomy patients received no radiotherapy. Pathologic complete response was defined as the absence of invasive tumor in the breast. Multivariate analyses were used to identify independent predictors of LRR. The primary end point was time to LRR as first event. Results: In 3,088 patients, 335 LRR events had occurred after 10 years of follow-up. The 10-year cumulative incidence of LRR was 12.3% for mastectomy patients (8.9% local; 3.4% regional) and 10.3% for lumpectomy plus breast radiotherapy patients (8.1% local; 2.2% regional). Independent predictors of LRR in lumpectomy patients were age, clinical nodal status (before NC), and pathologic nodal status/breast tumor response; in mastectomy patients, they were clinical tumor size (before NC), clinical nodal status (before NC), and pathologic nodal status/breast tumor response. By using these independent predictors, groups at low, intermediate, and high risk of LRR could be identified. Nomograms that incorporate these independent predictors were created. Conclusion: In patients treated with NC, age, clinical tumor characteristics before NC, and pathologic nodal status/breast tumor response after NC can be used to predict risk for LRR and to optimize the use of adjuvant radiotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Overgaard, M., Hansen, P. S., Overgaard, J., Rose, C., Andersson, M., Bach, F., Kjaer, M., Gadeberg, C. C., Mouridsen, H. T., Jensen, M.-B., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710023371401 · Cited by 2,554
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Self-citationFisher, B., Brown, A., Mamounas, E., Wieand, S., Robidoux, A., Margolese, R. G., Cruz, A. B., Fisher, E. R., Wickerham, D. L., Wolmark, N., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2483 · Cited by 1,801
Self-citationRastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789 · cited 2×
“5 years of follow-up.(13) B-27 was closed to follow-up on December 31, 2009.”
BackgroundSelf-citationAdjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast Cancer
Ragaz, J., Jackson, S. M., Le, N., Plenderleith, I. H., Spinelli, J. J., Basco, V. E., Wilson, K. S., Knowling, M. A., Coppin, C. M. L., Paradis, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710023371402 · Cited by 1,745
Overgaard, M., Jensen, M.-B., Overgaard, J., Hansen, P. S., Rose, C., Andersson, M., Kamby, C., Kjaer, M., Gadeberg, C. C., Rasmussen, B. B., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09201-0 · Cited by 1,602
Wolmark, N., Wang, J., Mamounas, E., Bryant, J., & Fisher, B. (2001) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003469 · Cited by 1,299
Self-citationThe Analysis of Failure Times in the Presence of Competing Risks
Prentice, R. L., Kalbfleisch, J. D., Peterson, A. V., Flournoy, N., Farewell, V. T., & Breslow, N. E. (1978) · Biometrics · doi:10.2307/2530374 · Cited by 1,266
Bear, H. D., Anderson, S., Brown, A., Smith, R., Mamounas, E. P., Fisher, B., Margolese, R., Theoret, H., Soran, A., Wickerham, D. L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.005 · Cited by 1,118
Self-citationEffects of Radiotherapy and Surgery in Early Breast Cancer — An Overview of the Randomized Trials
(1995) · New England Journal of Medicine · doi:10.1056/nejm199511303332202 · Cited by 1,012
Bear, H. D., Anderson, S., Smith, R. E., Geyer, C. E., Mamounas, E. P., Fisher, B., Brown, A. M., Robidoux, A., Margolese, R., Kahlenberg, M. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1665 · Cited by 943
Self-citationClarke, M. J., Collins, R., Davies, C., Godwin, J., Gray, R. G., & Peto, R. (2000) · The Lancet · Cited by 824
Effects of Radiotherapy and Surgery in Early Breast Cancer — An Overview of the Randomized Trials
(1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341522 · Cited by 783
Recht, A., Gray, R., Davidson, N. E., Fowble, B. L., Solin, L. J., Cummings, F. J., Falkson, G., Falkson, H. C., Taylor, S. G., & Tormey, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.6.1689 · Cited by 440
Howell, A., Ribeiro, G. G., & Swindell, R. (1995) · Cited by 410
The Use and Interpretation of Competing Risks Regression Models
Dignam, J. J., Zhang, Q., & Kocherginsky, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2097 · Cited by 357
Self-citationWallgren, A., Bonetti, M., Gelber, R. D., Goldhirsch, A., Castiglione-Gertsch, M., Holmberg, S. B., Lindtner, J., Thürlimann, B., Fey, M., Werner, I. D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.130 · Cited by 272
Cited by
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., Freedman, G., Houssami, N., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3481-4 · Cited by 612
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., Freedman, G., Houssami, N., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.11.012 · Cited by 495
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., Freedman, G., Houssami, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.3935 · Cited by 451
Metadata
- Authors
- Mamounas, E. P., Anderson, S. J., Dignam, J. J., Bear, H. D., Julian, T. B., Geyer, C. E., Taghian, A., Wickerham, D. L., & Wolmark, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-11-10
- Volume
- 30
- Issue
- 32
- Pages
- 3960-3966
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2107073127
- Cited by
- 587
- References
- 22
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.